CVS (CVS) Q2 2025: Pharmacy Script Share Climbs to 27.8% as Cost Advantage Model Gains Traction
CVS delivered broad-based revenue growth and raised guidance, but underlying margin pressures in healthcare delivery and group Medicare Advantage temper the outlook. Pharmacy and consumer wellness outperformed, driven by technology investment, market disruption, and the company’s cost advantage reimbursement model. Investor focus shifts to the pace of margin recovery in Aetna and Oak Street, as well as the sustainability of retail share gains and PBM retention into 2026.
Summary
- Pharmacy Script Share Expansion: CVS grew retail pharmacy script share to 27.8% as Rite Aid disruption and technology investments paid off.
- Margin Recovery Remains a Priority: Aetna and Oak Street margin headwinds persist, with multi-year repricing efforts underway.
- Guidance Raised Amid Mixed Segment Performance: Full-year outlook increased, but caution remains around healthcare delivery and macro trends.
Performance Analysis
CVS posted enterprise revenue growth across all segments, with pharmacy and consumer wellness revenue up over 12% and same-store pharmacy sales up more than 18%. The pharmacy business benefited from prescription and front store volume gains, as well as the early impact of Rite Aid script acquisitions.
Healthcare benefits (Aetna) saw revenue climb over 11%, yet underlying medical membership declined by 350,000 sequentially, reflecting disciplined pricing and the wind-down of the individual exchange product. Adjusted operating income in healthcare benefits jumped nearly 40% year-over-year, largely due to favorable risk adjustment updates and prior period development, but these were offset by a $470 million premium deficiency reserve (PDR) in group Medicare Advantage. Health services operating income fell 18%, pressured by higher medical benefit ratios at Oak Street and pharmacy client price improvements, despite strong PBM retention and new business wins.
- Retail Pharmacy Outperformance: Pharmacy and consumer wellness adjusted operating income rose nearly 8%, with script growth and front store gains offsetting reimbursement pressure.
- Healthcare Delivery Headwinds: Oak Street at-risk membership grew 31%, but medical cost pressures drove segment margin erosion.
- Cash Flow and Leverage: Operating cash flow reached $6.5 billion year-to-date, supporting $1.7 billion in dividends and progress on leverage reduction, though the ratio remains above long-term targets.
Segment divergence is pronounced: Pharmacy and PBM execution are offsetting healthcare delivery margin drag, with Aetna’s group Medicare repricing and Oak Street cost management as key watchpoints for the second half.
Executive Commentary
"We are seeing the impact of our intense focus on the execution within our pharmacy businesses while managing incremental pressure and healthcare delivery. We are encouraged by our enterprise performance and revised outlook, especially in this very dynamic environment."
David Joyner, President and Chief Executive Officer
"Second quarter revenues of nearly $99 billion increased approximately 8% over the prior year quarter driven by revenue growth across all segments. We delivered adjusted operating income of approximately $3.8 billion during the prior year quarter. An increase of nearly 2% from the prior year quarter driven by increases in our healthcare benefits and pharmacy and consumer wellness segments, partially offset by a decline in our health services segment."
Brian Newman, Chief Financial Officer
Strategic Positioning
1. Pharmacy Cost Advantage Model Drives Predictability
CVS cost advantage, the company’s cost-based pharmacy reimbursement model, is now fully implemented in commercial contracts and is tracking in line with expectations. This model aligns reimbursement more closely with drug acquisition cost, reducing cross-subsidization and creating transparency for payers. Management is preparing to extend this approach to government programs in 2026, aiming to stabilize reimbursement erosion and improve long-term pharmacy margins.
2. Aetna Margin Recovery Is a Multi-Year Effort
Aetna’s margin recovery plan is showing early progress, with operational improvements, technology investments, and disciplined pricing. However, group Medicare Advantage remains pressured by elevated medical cost trends and multi-year contract cycles. Approximately half of group MA revenue will reprice in 2026, but management cautions that full margin normalization may require more than one cycle due to the magnitude of dislocation.
3. Oak Street and Healthcare Delivery Under Scrutiny
Oak Street, CVS’s value-based care platform, continues to face elevated medical benefit ratios, driven by higher-acuity patient mix and robust supplemental benefits. Leadership is focused on technology enhancements, operational tightening, and measured center expansion to improve cost management. Signify Health, the in-home assessment business, partially offsets these pressures with strong volume growth.
4. PBM Retention and Innovation Fuel Growth
Caremark, CVS’s pharmacy benefit manager (PBM), reports high-90s retention rates and new client wins, including CalPERS, on the strength of performance-based pricing and cost-lowering innovation (e.g., GLP-1 formulary management, biosimilars). The 2026 selling season is off to a strong start, with clients citing transparency and clinical quality as differentiators.
5. Retail Front Store and Market Disruption
Front store sales and share are rising, benefiting from pharmacy adjacency, consumer marketing, and market disruption as competitors exit. Management highlights deliberate efforts to create value for consumers and drive foot traffic, with technology and operational investments supporting sustained gains.
Key Considerations
CVS’s quarter highlights the tension between strong retail/PBM execution and persistent healthcare delivery margin headwinds. Strategic initiatives are underway, but the path to normalized profitability in Aetna and Oak Street will require sustained discipline and operational rigor.
Key Considerations:
- Margin Recovery Timeline: Multi-year repricing in group Medicare Advantage and operational improvements in Oak Street are crucial for long-term earnings power.
- Pharmacy Model Durability: Cost advantage adoption and market disruption are driving share gains, but the sustainability of front store growth and script volume will be tested as competitive dynamics evolve.
- PBM Retention and Pricing Discipline: High retention and new wins validate CVS’s value proposition, but pricing competition and cost management remain ongoing risks.
- Cash Flow and Capital Allocation: Strong cash generation supports dividends and leverage reduction, yet balance sheet discipline is needed as margin recovery progresses.
- Regulatory and Policy Shifts: IRA impacts, CMS guidance, and reimbursement landscape changes could drive further volatility in government-related businesses.
Risks
Margin normalization in Aetna and Oak Street depends on successful repricing and cost control, which may take multiple contract cycles. Regulatory shifts, policy changes in Medicare/Medicaid, and evolving drug pricing dynamics could materially impact segment performance. Persistent reimbursement pressure in pharmacy, as well as macroeconomic or consumer headwinds, remain key factors to monitor.
Forward Outlook
For Q3 2025, CVS guided to:
- Continued cautious outlook on medical cost trends, especially in group Medicare Advantage and Oak Street
- Stable to improving pharmacy and consumer wellness performance, contingent on vaccine demand and consumer spending
For full-year 2025, management raised guidance:
- Adjusted EPS of $6.30 to $6.40 (up from $6.00 to $6.20 previously)
- Total revenue of at least $391.5 billion (up $9 billion from prior guidance)
- Operating income outlook increased, with pharmacy and consumer wellness up $200 million and health services down $200 million, reflecting Oak Street pressure
Management highlighted several factors that will shape the back half:
- Margin recovery in Aetna and Oak Street remains a multi-year journey
- Pharmacy cost advantage model and PBM innovation are expected to drive continued share gains
Takeaways
CVS’s diversified model is delivering revenue growth and supporting guidance raises, but the company’s long-term valuation hinges on margin normalization in healthcare delivery and insurance.
- Retail and PBM Strength: Technology-driven pharmacy execution and PBM innovation are offsetting reimbursement headwinds and fueling share gains.
- Margin Headwinds Persist: Group Medicare Advantage and Oak Street require disciplined repricing and operational improvement to restore profitability.
- Investor Watchpoints: Track the pace of Aetna and Oak Street margin recovery, PBM contract retention, and the sustainability of retail share gains into 2026.
Conclusion
CVS is leveraging its scale and pharmacy innovation to drive top-line growth, but its long-term earnings power will be determined by the success of multi-year margin recovery efforts in Aetna and Oak Street. Investors should monitor execution on cost advantage, PBM retention, and healthcare delivery turnaround as the key levers for valuation upside.
Industry Read-Through
CVS’s experience underscores the growing bifurcation in healthcare between retail/PBM performance and insurance/delivery margin pressure. The company’s shift to cost-based pharmacy reimbursement and PBM transparency is likely to accelerate industry-wide pricing evolution, pressuring smaller competitors to adapt or exit. Value-based care platforms face continued margin risk as higher-acuity patient populations and supplemental benefit inflation drive up costs. For peers and suppliers, the focus on technology, operational rigor, and contract repricing will be critical to navigating reimbursement pressure and policy volatility in the evolving healthcare landscape.